The Hypothesis

I suspect young-donor fecal microbiota transplantation (FMT) rejuvenates aged tissues by re-establishing a strict metabolic selection pressure rather than simply "purifying" mitochondrial DNA (mtDNA). It’s less about cleaning house and more about rebalancing the heteroplasmic portfolio. Instead of viewing heteroplasmy as a random accumulation of mistakes, we should see it as a dynamic fitness landscape where the microbiome dictates selective pressure. In this model, aging involves a "metabolic drift" where a senescent microbiome stops providing the metabolite cues—like SCFAs and secondary bile acids—needed to prune bad mtDNA variants. Young FMT brings these cues back, creating a "metabolic bottleneck" that favors variants built for efficient oxidative phosphorylation and adaptive stress response.

Mechanistic Reasoning

Evidence suggests mitochondrial heteroplasmy is actually an evolved bet-hedging strategy, where variance allows cells to survive shifting metabolic demands. But as the gut microbiome turns pro-inflammatory with age, we lose the diversity of short-chain fatty acids (SCFAs) like butyrate that normally tune mitochondrial function.

When microbial diversity drops, selective pressure on the mitochondrial population relaxes. Without the "metabolic discipline" provided by young-donor metabolites, heteroplasmy shifts from a functional portfolio toward high-variance noise. Introducing a young microbiome effectively changes the environment-dependent fitness landscape of the cell.

Specifically, I posit that:

1. Metabolite-Driven Selection: Young-donor metabolites like Urolithin A or butyrate act as selective agents, raising the metabolic cost of carrying inefficient mtDNA variants.
2. ROS-Mediated Culling: The shift in host ROS levels triggered by microbiome signals shapes the mitochondrial population. This selectively triggers mitophagy in organelles with high mutation loads while sparing those that help the cell stay resilient.
3. Tissue-Specific Tuning: We’ll likely see this most clearly in high-turnover tissues like the intestinal epithelium and hematopoietic stem cells (HSCs), where FMT's rejuvenation potential is already documented.

Challenging the "Clean Genome" Orthodoxy

This idea pushes back against longevity interventions that try to wipe out heteroplasmy entirely. If heteroplasmy is a form of biological insurance, "cleaning" the genome down to a single wild-type clone might leave us with high-performance mitochondria that can’t handle environmental shocks. If young FMT works by optimizing rather than eliminating this variance, then our goal shouldn't be zero variance, but a "youthful" balance.

Testability and Falsification

We can test this using single-cell mtDNA sequencing (scmtDNA-seq) on HSCs and intestinal crypt cells in aged mice (20+ months) given young-donor versus age-matched FMT.

• Support for Hypothesis: Following young FMT, we should see a statistically significant reduction in the variance of deleterious variants across the cell population, along with the stabilization (but not elimination) of specific low-frequency variants that correlate with better metabolic markers.
• Falsification: If FMT improves physiological markers like grip strength or glucose tolerance but the heteroplasmy distribution looks just like the aged controls—or shows random drift—then the effect is probably coming from nuclear gene expression or epigenetic remodeling rather than organellar population dynamics.